Updated September 2026. By Remy Beaumont.
Total raised in confirmed US startup funding rounds this week: approximately $800m+ across 10+ disclosed deals.
The headline raise: Enveda, $311m Series E
Boulder, Colorado. AI drug discovery. Led by Catalio Capital Management, with Surveyor Capital, T. Rowe Price, Lux Capital, and a sovereign wealth fund participating. Valued at roughly $2 billion.
Enveda is not selling AI tools to pharma. It is building the drug assets itself, using metabolomics, machine learning, and proprietary biological datasets to find therapeutically useful chemistry from natural compounds. Total funding now exceeds $845m.
The distinction matters enormously. Software-only discovery platforms face commoditisation pressure as foundation models improve. Enveda has moved into clinical development, which means investors are underwriting the possibility of owned drug candidates with potential market exclusivity, not just a platform fee.
The investor mix tells you where this sits on the maturity curve. Catalio and Lux bring deep life-sciences expertise. T. Rowe Price and Surveyor bring crossover capital that typically appears when a company is being capitalised for multiple exit paths. At $2 billion, the valuation now depends more on clinical outcomes than on further AI platform improvements.
How they announced it
The Wall Street Journal broke the news, positioning it as Enveda doubling its valuation. No founder-led social media blitz. No product demo tied to the announcement. This was a classic institutional biotech fundraise announcement: let the Journal carry the credibility, let the numbers speak.
For a company at this stage, that is the right call. Enveda does not need to build consumer awareness. It needs to signal clinical seriousness to potential pharma partners, future public-market investors, and the scientific talent pipeline. A WSJ exclusive does all three without the noise.
What founders can take from this
Own the asset, not just the platform. AI-discovery companies that only sell software face one set of economics. Companies that use AI to own therapeutic assets can capture pharmaceutical-scale value. Enveda's repeated large rounds prove investors will fund that model at scale, but you need wet-lab capability and clinical risk appetite to match.
Match your announcement channel to your audience. A WSJ exclusive says "institutional credibility" in a way that a founder LinkedIn post cannot. If your next raise is about signalling to large institutional investors or potential acquirers, consider a single authoritative outlet over broad social distribution.
Let your cumulative funding tell the growth story. Enveda did not need to overexplain its technology. $845m in total funding and a $2 billion valuation communicate momentum on their own. Sometimes the numbers are the narrative.
Other notable US rounds this week
Hubble Network, $200m Series C, Seattle. Satellite Bluetooth connectivity. Led by Smith Point Capital. Valued at $1.6 billion. Hubble is building satellites that connect directly to ordinary Bluetooth devices, bypassing the need for expensive terminals. If it works at scale, it could embed satellite connectivity into logistics, agriculture, asset tracking, and defence without requiring proprietary hardware.
Brahma AI, $150m preferred equity, Los Angeles/London/Mumbai. Enterprise audiovisual AI infrastructure. Multiples Alternate Asset Management invested $100m of the round. Customers include Warner Bros., the NBA, and Mayo Clinic. Brahma is positioning itself as the system enterprises trust around synthetic content workflows, rights, provenance, and deployment, not just another generation interface.
Ema, $77m Series B, Mountain View. Enterprise AI agent orchestration. Led by Creaegis, with Accel, Section 32, and Prosus. Ema coordinates teams of AI agents across HR, finance, and IT. Revenue reportedly expanded roughly 50-fold in two years, with multiyear contract bookings exceeding $150m. Their outcome-based pricing model, charging for completed processes rather than seats, is a signal of where enterprise AI economics are heading.
Pilgrim, $25m seed, United States. Biosecurity and field-deployable biological threat detection. Buckley led the round at a reported $150m valuation. The device combines air sampling with genomic sequencing. With backers connected to Anthropic, this sits at the intersection of AI capability and AI safety: as biological design tools improve, detection infrastructure becomes a parallel investment thesis.
